Medicine industry or meet the peak of restructuring

Source: Beijing business daily, 2014-12-09, M & A and restructuring among domestic pharmaceutical enterprises continued to heat up in 2014, and will reach a peak in the second half of 2015 or 2016 After the "Song Lin incident" of Cr Pharma, the reorganization was once stranded Recently, Fu Yuning, chairman of China Resources Group, who has been appointed for nearly 8 months, began to serve as chairman of China Resources Pharmaceutical Co., Ltd., which is understood by the industry as the "first fire" after Fu Yuning took over China Resources Group Fu Yuning has been focusing on China Resources medicine, which has been taking a radical step in the field of medicine, and has become the focus of attention in the industry after gradually moving away from the "Song Lin era" Recently, internal information of China Resources Group said that the group has adjusted the senior management team of China Resources medicine Fu Yuning, chairman of China Resources Group, concurrently serves as chairman of China Resources Pharmaceutical Group, Li fuzuo, former chairman of China Resources pharmaceutical Holding Co., Ltd serves as vice chairman of China Resources pharmaceutical, and Wang Chuncheng, former chairman of China Resources Textile Co., Ltd serves as chairman of China Resources pharmaceutical Holding Co., Ltd "The chairman of the group also serves as the leader of the subordinate companies China Resources pharmaceutical is the first one It can be understood that the group attaches more importance to the pharmaceutical sector, but the specific strategic investment of the group in the pharmaceutical sector has not been updated." The head of China Resources pharmaceutical told Beijing business daily On the evening of April 17 this year, the Central Commission for Discipline Inspection announced that Song Lin, chairman of China Resources Group, was investigated for suspected serious violations of laws and disciplines On April 23, Fu Yuning, chairman of China Merchants Group, who was also the chairman of the central enterprises in Hong Kong, was appointed as the new chairman of China Resources Group Shortly after Fu Yuning took office, he said in a speech at the group cadres' meeting that he would cooperate with the organization to investigate the "Song Lin incident" In the process, we should comprehensively review and reflect on the problems accumulated by China Resources in the past rapid development, especially the problems exposed in the process of acquisition, merger and reorganization, carefully review the loopholes in the system, eliminate the accumulated disadvantages with the courage of scraping the bone and treating the poison, and improve the company's management system In the view of the industry, "problems exposed in the process of acquisition, merger and reorganization" refers to the radical expansion of the pharmaceutical sector According to statistics, in recent years, more than ten internal integrations have been carried out in China Resources pharmaceutical, and more than 80 subsidiaries have been acquired by China Resources pharmaceutical commercial company In addition, China Resources Group has seven business sectors, including consumer goods, power, real estate, cement, gas, medicine and finance In 2013, the sales and total assets of China Resources medicine exceeded 100 billion yuan, which is the fastest-growing and highest rate of return industry sector among the seven industries of China Resources Group For the transfer of senior management positions of China Resources pharmaceutical, Shi lichen, partner of Peking University Zongheng pharmaceutical, believes that the growth of energy and other businesses has slowed down, and medicine has become an important business pillar of the group The group attaches great importance to the pharmaceutical sector The chairman of the group serves as the chairman of the pharmaceutical sector, which is also convenient for the overall adjustment of resources of other sectors to be introduced into the pharmaceutical sector In addition, the position of the top leader in the pharmaceutical sector is vacant, and the company's internal people are unstable, which can pacify people and facilitate the re formulation and implementation of future strategies A personage in the industry who did not want to be named said that Fu Yuning's part-time job and transfer of senior managers to China Resources pharmaceutical is the group's new action in the pharmaceutical sector, and China Resources pharmaceutical sector is expected to become the first sector of the group to focus on reform and efforts In recent years, there are too many enterprises merged by the pharmaceutical sector, all of which are self-contained systems with their own R & D, production and sales systems China Resources has not yet integrated internal resources such as enterprise upgrading and positioning for the merged enterprises, so internal resource integration should be the first knife for Fu Yuning's operator China Resources pharmaceutical The best choice for expansion is 2010 China Resources Group and Beijing state owned assets supervision and Administration Commission jointly signed the restructuring agreement of Beijing Pharmaceutical Group Co., Ltd and China Resources Pharmaceutical Group Co., Ltd in the planning of China Resources Group, China Resources Pharmaceutical Group will pack its assets to go to Hong Kong as a whole within 2015 In the first half of this year, China Resources Pharmaceutical Co., Ltd has successively sold three nine chain drugstores and China Resources Wandong, and has successively withdrawn some retail drugstores and medical device businesses In April, China Resources Shuanghe and China Resources Sanjiu both suspended trading, triggering a new round of speculation on the integration of China Resources pharmaceutical assets, but later by the "Song Lin incident" Influence: both CR Sanjiu and Cr Shuanghe said that the controlling shareholders are studying the asset restructuring plan according to the recent changes in internal and external conditions It is estimated that the asset restructuring plan cannot be determined in the short term, so they decided to terminate the planning of this major asset restructuring "At present, there is no new progress and no specific time for listing." China Resources pharmaceutical said According to the above insiders, "listing in 2015 is not the best time China Resources pharmaceutical is unstable internally Affected by negative news, its market value cannot reach the highest value." According to schlichen's further analysis, "the pharmaceutical sector should continue to grow stronger and larger, and M & A and listing are still the final strategic ways to be implemented, but the overall pace will slow down And Fu Yuning is a low-key person, but he has a style of work, but now he is still in the internal research period, and has not made a clear overall plan for the pharmaceutical sector " In one year or in March of this year, the State Council's opinions on further optimizing the market environment for enterprise merger and reorganization was issued, which created a good policy environment for merger and reorganization, and thus became an important driving factor for the accelerated development of merger and reorganization in the pharmaceutical industry this year According to incomplete statistics, since this year, there have been more than 200 M & A and restructuring events in the pharmaceutical industry, involving more than 60 billion yuan The growth rate is higher than that of the previous two years The M & A and restructuring of the entire pharmaceutical industry is in the stage of heating up and accelerating "But it has not yet reached the climax of restructuring." "With the promotion of a series of national policies and the expiration of the new GMP and GSP by the end of 2015, nearly a quarter of pharmaceutical enterprises are expected to fail to meet the new GMP If these enterprises are to be acquired, they will either close down," the pharmaceutical industry said So the second half of 2015 or 2016 will reach the peak of M & A and restructuring of the whole pharmaceutical industry " Analysts said that compared with the international market, the domestic pharmaceutical market still has a huge growth space At present, the proportion of health expenditure to GDP is only 5.2% in China and 17.9% in the United States In order to realize the extension growth, the merger and reorganization of the pharmaceutical industry will appear on a large scale "CR Pharma obviously does not want to lose this opportunity Previously, it was incomprehensible that CR Pharma sold Sanjiu drugstore and Cr Wandong successively Therefore, in the future development, the distribution of medical devices and drugs must be accelerated, perhaps in the way of merger and reorganization Other large pharmaceutical enterprises also need to seize more medical and pharmaceutical resources in advance, so as to obtain development opportunities in the future competition, including large pharmaceutical enterprises such as Sinopharm, Shanghai Pharmaceutical and China Pharmaceutical and healthcare " According to schlichen